Skip to main content

Table 1 Characteristics of eligible studies in the qualitative and quantitative synthesis

From: Clinicopathological and prognostic significance of nestin expression in patients with breast cancer: a systematic review and meta-analysis

Study Year Country Cancer types Cases/controls Age (years) Follow-up time Method Cut-off value (positive/high) Survival outcomes Source of data NOS score
Asleh et al. [21] 2018 Canada IBC 339/2895 NR 12.6 years (median) IHC A2 > 0 BCSS(U), BCSS(M) Direct 8
Asleh et al. [52] 2019 Denmark MBC 29/216 NR NR IHC A2 > 0 OS(U), OS(M)
PFS(U), PFS(M)
Direct 8
De Lara et al. [22] 2019 Sweden MBC 25/110 NR 10 years IHC A2 > 0 OS(U), DMFS(U)
OS(M), DMFS(M)
Curve
Direct
8
Gao et al. [23] 2014 China BC 42/109 32–79 NR IHC A1 > 0 BCSS(U) Curve 8
Krüger et al. [24] 2017 Norway IBC I: 50/47
II: 35/244
III: 51/130
IV: 44/143
I: 50–69
II: 50–69
III, IV: NR
I: 13 years (median)
II, III, IV: NR
IHC At least 3 clearly positive cells I: BCSS(U), BCSS(M)
II, III, IV: NR
Direct 8
Liu et al. [26] 2010 China DCIS, IDC 24/126 27–80 NR IHC A5 > 0 BCSS(U) Curve 8
Liu et al. [25] 2012 China DCIS, IDC 62/241 NR 7.5 years IHC A5 > 0 BCSS(U) Curve 7
Meisen et al. [54] 2014 USA BC 83/83 NR NR qRT-PCR Median DMFS(U) Curve 7
Nowak et al. [50] 2017 Poland IDC 109 (total) NR NR IHC Nestin+ MVD
> 75.76 (median)
OS(U), OS(M), RFS(U) Direct curve 7
Nowak et al. [51] 2018 Poland IDC 39/83 NR 1–80 months IHC A3*B1 > 0 OS(U) Curve 7
Parry et al. [27] 2008 UK IBC 20/223 NR 5.2–135.3 months IHC A5 > 0 BCSS(U) Curve 8
Piras et al. [28] 2011 Italy BC 28/25 32–67 82–194 months IHC A6 > 0 OS(U) Curve 8
Tampaki et al. [55] 2017 Greece BC 26/115 NR NR IHC A4 > 0 RFS(U), RFS(M) Curve direct 7
Zhao et al. [20] 2014 China TNBC 41/109 NR NR IHC A1 > 0 OS(U) Curve 7
Zhu et al. [56] 2009 China DCIS, IDC 20/100 NR NR IHC A5 > 0 NR NR
  1. IBC invasive breast cancer, MBC metastatic breast cancer, BC breast cancer, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, TNBC triple-negative breast cancer, BCSS breast cancer-specific survival, OS overall survival, PFS progression-free survival, DMFS distant metastasis-free survival, RFS recurrence-free survival, NR not reported, U univariate analysis, M multivariate analysis
  2. A: percentage of positive cells. A1: scored 0 (< 1%), 1 (1–9%), 2 (≥ 10%); A2: scored 0 (< 1%), 1 (≥ 1%); A3: scored 0 (0%), 1 (< 10%), 2 (10–50%), 3 (51–80%), 4 (> 80%); A4: scored 0 (≤ 5%), 1 (> 5%); A5: scored 0 (< 1%), 1 (1–9%), 2 (≥ 10%); A6: scored 0 (< 10%), 1 (≥ 10%)
  3. B: intensity of staining. B1: scored 0 (absence of staining), 1 (weak staining), 2 (moderate staining), 3 (strong staining)